

Mumps Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/M7F6095637B2EN.html>

Date: March 2022

Pages: 36

Price: US\$ 2,000.00 (Single User License)

ID: M7F6095637B2EN

Abstracts

Mumps Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1, 2 and 3 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Mumps - Overview

Mumps - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mumps - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Mumps - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Daiichi Sankyo Co Ltd

GlaxoSmithKline Plc

Shanghai King-Cell Biotechnology Co Ltd

Sinovac Biotech Ltd

Zydus Lifesciences Ltd

Mumps - Drug Profiles

(measles + mumps + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella + varicella) vaccine - Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

(measles + mumps + rubella) vaccine - Drug Profile

Product Description

Mechanism Of Action

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3])

vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

mumps vaccine - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Mumps - Drug Profile

Product Description

Mechanism Of Action

VN-0102 - Drug Profile

Product Description

Mechanism Of Action

Mumps - Dormant Projects

Mumps - Product Development Milestones

Featured News & Press Releases

Aug 02, 2021: GSK files for licensure of MMR vaccine in the US

Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Mumps, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
Mumps - Pipeline by Daiichi Sankyo Co Ltd, 2022
Mumps - Pipeline by GlaxoSmithKline Plc, 2022
Mumps - Pipeline by Shanghai King-Cell Biotechnology Co Ltd, 2022
Mumps - Pipeline by Sinovac Biotech Ltd, 2022
Mumps - Pipeline by Zydus Lifesciences Ltd, 2022
Mumps - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Mumps, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Mumps Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/M7F6095637B2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M7F6095637B2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

